Premium
Dopamine agonists in the treatment of prolactinoma: are they still first choice?
Author(s) -
Ogilvie C. M.,
Milsom S. R.
Publication year - 2011
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/j.1445-5994.2010.02410.x
Subject(s) - prolactinoma , medicine , dopamine agonist , dopamine , cabergoline , prolactin , agonist , disease , pergolide , intensive care medicine , dopaminergic , receptor , hormone
Dopamine agonist therapy has been the cornerstone treatment for prolactinoma since the 1970s, replacing surgery in the primary management of this condition. These agents are effective in the management of prolactin excess, have a low side‐effect profile, and in some cases may even be curative. However, recent studies of high dose dopamine agonists used in Parkinson's disease have raised the possibility that these drugs may be associated with cardiac valvulopathy. This paper discusses the modern use of dopamine agonists in a patient with prolactinoma.